Zimbabwe Pharmaceuticals and Healthcare Report Q4 2017

BMI Industry View

Table: Headline Pharmaceuticals & Healthcare Forecasts (Zimbabwe 2015-2021)

SWOT

Industry Forecast

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales, Historical Data And Forecasts (Zimbabwe 2013-2021)

Healthcare Market Forecast

Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Zimbabwe 2013-2021)

Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Zimbabwe 2013-2021)

Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Zimbabwe 2013-2021)

Prescription Drug Market Forecast

Patented Drug Market Forecast

Generic Drug Market Forecast

Pharmaceutical Trade Forecast

Table: Pharmaceutical Trade Data And Forecasts (Zimbabwe 2015-2021)

Industry Risk/Reward Index

Sub-Saharan Africa Pharmaceuticals: Small Market Sizes Weaken Attractiveness To Innovative Drugmakers

Regulatory Review

Regulatory Regime

Intellectual Property Issues

Pricing And Reimbursement Regime

Market Overview

Healthcare Sector

Research & Development

Clinical Trials

Epidemiology

Competitive Landscape

Research-Based Industry

Table: Multinational Market Activity

Generic Drugmakers

Pharmaceutical Distribution And Retail Sector

Company Profile

Datlabs

Varichem Laboratories

Demographic Forecast

Table: Population Headline Indicators (Zimbabwe 1990-2025)

Table: Key Population Ratios (Zimbabwe 1990-2025)

Table: Urban/Rural Population & Life Expectancy (Zimbabwe 1990-2025)

Table: Population By Age Group (Zimbabwe 1990-2025)

Table: Population By Age Group % (Zimbabwe 1990-2025)

Glossary

Methodology

Pharmaceutical Expenditure Forecast Model

Healthcare Expenditure Forecast Model

Notes On Methodology

Risk/Reward Index Methodology

Table: Indicators - Rationale And Sources

Zimbabwe Pharmaceuticals and Healthcare Report Q4 2017

BMI View:

Zimbabwe's pharmaceutical market presents significant growth potential given itsunderdevelopment. However, a combination of economic and market challenges will ensure that it remainshighly challenging for multinational pharmaceutical firms to invest locally. As such, we expect theZimbabwean government to prioritise the local generic drug industry in order to control costs and boostdomestic drugmaker competitiveness. Besides encouraging greater investment into local drugmanufacturing, the government's pro-generic drug policy on imports will need to be altered in order toadvance local firms' position in the market.

Headline Expenditure Projections

Pharmaceuticals: USD396mn in 2016 to USD413mn in 2017; +4.3% in US dollar terms. Forecastunchanged from previous quarter.

Healthcare: USD897mn in 2016 to USD863mn in 2017; -3.9% in US dollar terms. Forecast unchangedfrom previous quarter.

Risk/Reward Index

Sub-Saharan Africa is a region with high variability of market attractiveness for innovative drugmakers.While certain markets hold significant opportunities for the commercialisation of pharmaceuticals, theregion itself lags behind global standards in all areas given its underdeveloped nature. As such, it is vitalthat companies appreciate the varying levels of investment risks and rewards that are present in the marketsin Sub-Saharan Africa. BMI's Innovative Pharmaceuticals

Risk/Reward Index

tool, which provides aglobally comparative and numerically based assessment of a market's attractiveness for companies lookingto launch a high-value drug, was established to address this.